These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34970366)

  • 21. Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.
    Yamamoto Y; Takei K; Arulmozhiraja S; Sladek V; Matsuo N; Han SI; Matsuzaka T; Sekiya M; Tokiwa T; Shoji M; Shigeta Y; Nakagawa Y; Tokiwa H; Shimano H
    Biochem Biophys Res Commun; 2018 May; 499(2):239-245. PubMed ID: 29567478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
    Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
    J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.
    Fruchart JC
    Cardiovasc Diabetol; 2017 Oct; 16(1):124. PubMed ID: 28978316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
    Iwasaki M; Suzuki H; Umezawa Y; Koshida T; Saito M; Fukuda H; Takahara H; Matsuzaki K; Suzuki Y
    Medicine (Baltimore); 2023 Feb; 102(7):e32818. PubMed ID: 36800602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
    Fruchart JC; Hermans MP; Fruchart-Najib J; Kodama T
    Curr Atheroscler Rep; 2021 Jan; 23(1):3. PubMed ID: 33392801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
    Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
    Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
    Tanaka A; Nakamura T; Sato E; Chihara A; Node K
    CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease.
    Tamai H; Okamura J
    Hepatol Res; 2023 Mar; 53(3):258-266. PubMed ID: 36378065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.
    Araki M; Nakagawa Y; Oishi A; Han SI; Wang Y; Kumagai K; Ohno H; Mizunoe Y; Iwasaki H; Sekiya M; Matsuzaka T; Shimano H
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30041488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
    Horinouchi Y; Murashima Y; Yamada Y; Yoshioka S; Fukushima K; Kure T; Sasaki N; Imanishi M; Fujino H; Tsuchiya K; Shinomiya K; Ikeda Y
    Life Sci; 2023 May; 321():121590. PubMed ID: 36940907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate.
    Sasaki Y; Raza-Iqbal S; Tanaka T; Murakami K; Anai M; Osawa T; Matsumura Y; Sakai J; Kodama T
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease.
    Izumihara R; Nomoto H; Kito K; Yamauchi Y; Omori K; Shibayama Y; Yanagiya S; Miya A; Kameda H; Cho KY; Nagai S; Sakuma I; Nakamura A; Atsumi T
    Diabetes Metab J; 2024 May; 48(3):473-481. PubMed ID: 38419467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.
    Ida S; Kaneko R; Murata K
    Cardiovasc Diabetol; 2019 Mar; 18(1):38. PubMed ID: 30898163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model.
    Tomita Y; Ozawa N; Miwa Y; Ishida A; Ohta M; Tsubota K; Kurihara T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
    Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
    Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
    Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury.
    Konishi H; Miyauchi K; Onishi A; Suzuki S; Fuchimoto D; Shitara J; Endo H; Wada H; Doi S; Naito R; Ogita M; Dohi T; Kasai T; Daida H
    PLoS One; 2020; 15(11):e0241195. PubMed ID: 33201888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
    Steiner G
    Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.